Desogestrel/ethinyl estradiol

Selected Enskyce and Kariva prevent pregnancy in patients electing oral contraception. These are not progestin-only desogestrel pills or established emergency-contraception products. Neither protects against HIV or other sexually transmitted infections; use appropriate STI prevention. This review focuses on these two verified monophasic/estrogen-tail packs, not every triphasic brand or off-label treatment.

Reliable daily use matters. Current CDC estimates approximately seven pregnancies per hundred CHC users in the first year of typical use, which differs from older selected-label study tables. Discuss goals, contraindications and alternatives rather than promise a universal one-percent failure rate or automatically select this progestin for every patient.

Take one tablet by mouth at the same time daily. Enskyce uses 21 combination tablets followed by seven inactive reminders; Kariva uses 21 combination tablets, two inactive tablets and five estrogen-only tablets. Start the next pack the day after the last tablet. Do not infer that every green/blue/white tablet has the same ingredients across manufacturers.

Selected labels describe Day 1 and Sunday starts; Sunday start requires an additional contraceptive method through the first seven consecutive combination-tablet days. Day 1 begins with normal menstrual onset after pregnancy assessment. Current CDC permits assessed initiation whenever pregnancy can reasonably be excluded, using seven-day back-up when starting more than five days after bleeding began. Switching and postpartum initiation need a written clinician plan based on the exact product and eligibility.

Obtain the exact pack’s missed-tablet instructions and prompt clinician/pharmacist advice after misses, vomiting or severe diarrhea. Current CDC addresses hormonally active missed pills; extending the hormone-free interval is particularly risky and seven continuous CHC days are needed for reliable ovulation prevention. Label week/start-day catch-up rules differ from the current simplified CDC approach, and Kariva has an estrogen-only tail. This profile does not merge them into an unvalidated tail-tablet algorithm. Assess back-up, emergency contraception and pregnancy testing promptly when indicated.

There is no validated renal/hepatic dose-reduction table; lowering a tablet dose does not correct estrogen-related contraindications. Current CDC considers nephrotic syndrome and hemodialysis/peritoneal dialysis unacceptable-risk CHC settings. Liver disease eligibility depends on severity and diagnosis. Obtain an alternative-method assessment rather than invent half-tablet or dialysis supplements.

Do not use with known/current-history thromboembolic disease, relevant cerebrovascular/coronary disease, current/history breast cancer, listed liver tumors/cholestatic conditions, unexplained genital bleeding or the contraindicated ombitasvir/paritaprevir/ritonavir±dasabuvir regimen. Enskyce also explicitly lists thrombophilia, complicated valvular disease, severe persistent hypertension, vascular diabetes, focal neurologic headaches, major surgery with prolonged immobility, pregnancy and ingredient allergy. Current CDC additionally makes migraine with aura and specified high-risk CKD settings unacceptable risk; older Kariva §Contraindications omissions do not establish safety in those conditions.

Both selected labels carry the cigarette-smoking/serious cardiovascular-events warning: patients over thirty-five who smoke should not use these COCs. Risk rises with age and smoking exposure. Current CDC smoking classifications and the actual product warning guide selection; absence of heavy smoking does not negate other estrogen contraindications.

Possible effects include nausea, breast symptoms, spotting/bleeding changes, headache, mood changes, edema and pigment changes. Serious events include thrombosis, stroke/MI, liver complications and significant hypertension. Pregnancy must be considered with missed bleeding and adherence lapses; do not automatically treat prolonged bleeding or amenorrhea by raising estrogen exposure. Historical class rates and study formulations are not exact personal predictions.

Rifampin/rifabutin, carbamazepine, phenytoin, other relevant anticonvulsants and St. John’s wort can reduce contraceptive exposure/effectiveness. Enskyce explicitly advises alternate/back-up contraception during inducer use and for 28 days after stopping; apply the exact co-medication and contraceptive plan. Older Kariva wording suggests ampicillin/tetracycline effects, but current CDC states most broad-spectrum antibiotics do not reduce CHC efficacy. Do not universalize antibiotic failure or apply that reassurance to rifamycins.

Estrogen-containing COCs can substantially lower lamotrigine concentrations and impair seizure control; starting/stopping or hormone-interval changes require coordinated monitoring/dose management. Other interactions can raise hormone/substrate levels or alter thyroid replacement needs. Enskyce describes reduced interaction when colesevelam is separated by four hours. Review actual drug labels rather than assume contraceptive efficacy is fixed by a generic spacing rule.

Ombitasvir/paritaprevir/ritonavir with or without dasabuvir is contraindicated because of ALT elevations; labels advise discontinuation before treatment and possible restart about two weeks after completion under clinical direction. Kariva also says glecaprevir/pibrentasvir co-use is not recommended. Dose-dependent co-medication labeling can evolve: check the exact HCV product before selecting contraception rather than extrapolate from an old class list.

Use is intended after menarche in patients of reproductive potential, with expected adolescent efficacy similar to adults. Not indicated before menarche. Enskyce is not indicated over sixty-five; neither selected contraceptive is a menopausal hormone-therapy substitute. Evaluate age plus smoking/BP/migraine and clot risks, not age alone.

Stop contraceptive treatment if pregnancy occurs; inadvertent early exposure does not establish a pregnancy-treatment indication. Labels describe nonbreastfeeding initiation no earlier than four weeks postpartum; current CDC excludes CHCs below twenty-one days and stratifies days 21–42 by VTE risk and feeding. The reviewed label’s four-week sentence is not a universal safe restart: clinicians must assess eligibility and back-up. Confirm pregnancy when missed bleeding and adherence history warrant it.

Selected older labels favor another method until weaning because hormones enter milk and COCs can reduce milk production. Current CDC distinguishes feeding establishment and timing: breastfeeding patients generally should not use CHCs before thirty days; days 30–42 depend on VTE risk, and after forty-two days use is generally acceptable with assessment. These frameworks are stated separately; no claim of absent milk transfer or automatic safety at four weeks is made.

No numeric organ adjustment or dialysis regimen is validated. Severe kidney/mineral or thrombotic conditions, vascular diabetes, hypertension and certain liver disease/tumors can make estrogen inappropriate. Current CDC: controlled or 140–159/90–99 hypertension generally should not use CHCs; ≥ 160/100 or vascular disease should not use. Consider diagnostic severity and all coexisting risks instead of lowering the hormone tablet dose.

Gonadotropin suppression inhibits ovulation, with additional cervical-mucus/endometrial changes. Desogestrel rapidly becomes active etonogestrel (3-keto-desogestrel), with hepatic/intestine metabolism and protein binding; EE undergoes conjugation and enterohepatic cycling. Low intrinsic androgenic activity in receptor/animal studies does not prove absence of thrombotic or metabolic risk.

Enskyce reports steady-state active-metabolite half-life about 38 hours and EE about 26 hours; Kariva reports about 28 and 24 hours for its combination tablet, with different EE-only-tail data. These variable study estimates are not a safe missed-dose window, an organ-impairment reduction table or grounds to interchange the 20/30-mcg packs.

Measure BP before initiation and reassess BP and relevant health/medication changes during routine visits. Evaluate clot risk, smoking, migraine/aura, liver/renal history, bleeding, mood and adherence. Current CDC does not require a routine pelvic examination, glucose/lipid/liver panel or thrombophilia screening solely to initiate in otherwise healthy patients; diagnosed conditions may need targeted tests. Older annual-exam label prose is not converted into a barrier to initiation.

Keep tablet order, start-day, missed-dose/back-up plan and refills clear. Obtain prompt advice after missed pills/GI illness or interacting-drug changes. Urgent care is needed for chest pain/dyspnea, painful swollen leg, sudden severe headache/focal signs, or vision loss; report jaundice, major depression and persistent abnormal bleeding. Discuss STI protection and reliable alternatives when daily adherence is difficult.

Enskyce 28-tablet blister NDC 68180-739-71: light-orange active L/J7, green inactive LU/L22. Kariva six-blister carton NDC 0555-9050-58: white combination dp/021, light-green inactive dp/331, light-blue EE-only dp/022. Kariva counseling contains a light-orange-tablet reference inconsistent with its own description/pack; identity here follows actual description and How Supplied. Verify dispensing package.

Enskyce combination tablet contains desogestrel 0.15 mg and EE 0.03 mg (30 mcg), with seven inert tablets. Kariva contains 0.15 mg/0.02 mg (20 mcg) combination tablets, two inert tablets and five EE-only 0.01 mg (10 mcg) tablets. Different triphasic packs/brands are not assumed interchangeable and require their exact label.

Enskyce: 25°C with permitted 15–30°C excursions. Kariva: 20–25°C controlled room temperature. Keep the pack intact to preserve order, out of children’s reach and use the labeled expiry. No universal after-opening discard period or pill-splitting regimen is supplied.